Ipamorelin 10mg – PharmaTech

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue and selective agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor.

Unlike native growth hormone or GHRH analogues, Ipamorelin acts through the ghrelin receptor system to stimulate endogenous growth hormone (GH) secretion. Its molecular structure was developed to provide potent GH-releasing activity with a high degree of selectivity within the growth hormone secretagogue class.

Ipamorelin has been investigated extensively in growth hormone physiology, endocrine signaling, gastrointestinal biology, metabolic research, and pharmacokinetic/pharmacodynamic studies.

OVERVIEW

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue and selective agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor.

Unlike native growth hormone or GHRH analogues, Ipamorelin acts through the ghrelin receptor system to stimulate endogenous growth hormone (GH) secretion. Its molecular structure was developed to provide potent GH-releasing activity with a high degree of selectivity within the growth hormone secretagogue class.

Ipamorelin has been investigated extensively in growth hormone physiology, endocrine signaling, gastrointestinal biology, metabolic research, and pharmacokinetic/pharmacodynamic studies.


MECHANISM OF ACTION

Ipamorelin binds to and activates GHS-R1a, a G-protein-coupled receptor expressed in the pituitary and several peripheral tissues.

Activation of GHS-R1a initiates intracellular signaling involving Gαq/11, phospholipase C and downstream calcium-dependent signaling, ultimately promoting GH release from pituitary somatotroph cells.

Principal Signaling Axis

Ipamorelin → GHS-R1a → Gαq/11 → PLC → intracellular Ca²⁺ signaling → GH secretion

Circulating GH subsequently interacts with the GH/IGF-1 axis, including stimulation of hepatic IGF-1 production.

Early pharmacological studies demonstrated that Ipamorelin produces potent GH release while showing substantially greater selectivity for GH secretion than several earlier growth hormone secretagogues.


KEY BENEFITS

Growth Hormone Research

  • Selective stimulation of endogenous GH secretion
  • GHS-R1a receptor activation
  • Investigation of pulsatile GH physiology
  • GH/IGF-1 axis research

Endocrine Research

  • Pituitary somatotroph signaling
  • Growth hormone secretagogue pathways
  • Neuroendocrine regulation
  • GHRH-independent GH stimulation

Metabolic Research

  • GH-associated lipid metabolism
  • Glucose homeostasis
  • Energy metabolism
  • Body-composition research

Gastrointestinal Research

  • Ghrelin-receptor signaling
  • Gastric motility
  • Gastrointestinal endocrine biology
  • Intestinal physiological responses

RESEARCH AREAS

Research Area Primary Focus
Growth Hormone Biology GH secretion and pituitary signaling
GHS-R1a Pharmacology Ghrelin-receptor activation
Endocrinology GH/IGF-1 axis
Neuroendocrinology Hypothalamic-pituitary signaling
Metabolic Research Energy, lipid and glucose metabolism
Gastrointestinal Biology Ghrelin signaling and gastrointestinal motility
Pharmacokinetics Peptide exposure and systemic clearance
Pharmacodynamics Relationship between Ipamorelin exposure and GH response

SCIENTIFIC EVIDENCE

Ipamorelin was originally characterized as a potent GH-releasing peptide with activity demonstrated in both in vitro pituitary-cell systems and animal models. Its pharmacological profile distinguished it from earlier secretagogues through its comparatively selective stimulation of GH.

Human pharmacokinetic/pharmacodynamic research has also been conducted. In healthy male volunteers receiving controlled intravenous infusions, Ipamorelin demonstrated dose-proportional pharmacokinetics and a reported terminal half-life of approximately 2 hours. GH concentrations reached a peak approximately 0.67 hours after administration in the studied model.

More recent regulatory review has continued to characterize Ipamorelin as a synthetic pentapeptide ghrelin mimetic acting primarily through GHS-R1a. The FDA review also notes that available nonclinical and clinical evidence does not establish Ipamorelin as an FDA-approved drug product.


MOLECULAR PROFILE

Parameter Specification
Compound Name Ipamorelin
Synonyms NNC-26-0161
Molecular Class Synthetic growth hormone secretagogue
Peptide Length 5 amino acids
Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular Formula C₃₈H₄₉N₉O₅
Molecular Weight ~711.9 Da
CAS Number 170851-70-4
Primary Target GHS-R1a / Ghrelin Receptor
Receptor Class G-protein-coupled receptor
Molecular Form Synthetic pentapeptide

The molecular sequence and physicochemical characteristics are consistent with the established chemical identity of Ipamorelin.

Peptide Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Where:

  • Aib = α-methylalanine
  • D-2-Nal = D-2-naphthylalanine
  • D-Phe = D-phenylalanine

The incorporation of non-standard and D-amino-acid residues contributes to the characteristic pharmacological profile of the molecule.


PHARMACOKINETIC & PHARMACODYNAMIC PROFILE

Pharmacodynamic Profile

Ipamorelin produces its primary pharmacodynamic effect through activation of GHS-R1a and stimulation of pituitary GH secretion.

Experimental pharmacology demonstrated high GH-releasing potency, while human studies confirmed a measurable relationship between circulating Ipamorelin concentrations and GH response.

The principal downstream endocrine pathway can be represented as:

GHS-R1a activation → GH release → GH receptor signaling → IGF-1 production

Pharmacokinetic Profile

Human pharmacokinetic research has reported:

Parameter Reported Profile
Population Studied Healthy adult male volunteers
Administration Studied Intravenous infusion
Terminal Half-Life ~2 hours
Clearance ~0.078 L/h/kg
Volume of Distribution at Steady State ~0.22 L/kg
GH Peak Response ~0.67 h
Dose Relationship Dose-proportional PK in studied range

These values derive from a controlled human PK/PD study and should not automatically be extrapolated to other formulations or routes of administration.


RESEARCH HIGHLIGHTS

Selective GH Secretagogue Activity

Ipamorelin was developed as a potent growth hormone secretagogue and demonstrated substantial selectivity for GH stimulation in early pharmacological studies.

GHS-R1a Activation

The peptide acts as an agonist at GHS-R1a, linking it mechanistically to the endogenous ghrelin signaling system.

Distinct From GHRH Analogues

Ipamorelin stimulates GH through the ghrelin/GHS-R1a pathway, which is pharmacologically distinct from direct activation of the growth hormone-releasing hormone receptor.

Human PK/PD Characterization

Controlled human studies have characterized the relationship between Ipamorelin exposure and GH secretion, providing substantially more pharmacokinetic information than is available for many experimental peptide secretagogues.

Gastrointestinal Biology

Because GHS-R1a is expressed in multiple peripheral tissues, Ipamorelin has also been investigated in gastrointestinal physiology, including gastric and intestinal motility research.


TECHNICAL SPECIFICATIONS

Specification PharmaTech Standard
Product Name Ipamorelin
Molecular Class Synthetic pentapeptide
Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular Formula C₃₈H₄₉N₉O₅
Molecular Weight ~711.9 Da
CAS 170851-70-4
Appearance White to off-white lyophilized powder
Identity Testing Mass Spectrometry
Purity Testing HPLC
Sequence Verification MS/MS / analytical characterization
Packaging PharmaTech specification
Lot Number PharmaTech lot-specific
Certificate of Analysis Available by lot

STORAGE & HANDLING

Ipamorelin should be maintained in its lyophilized form under controlled storage conditions and protected from:

  • Excessive heat
  • Moisture
  • Direct light
  • Repeated temperature fluctuations

PharmaTech lot-specific storage and handling specifications should be followed according to the corresponding product documentation and Certificate of Analysis.